Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04472494 · ClinicalTrials.gov registry record · Phase 2
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT04472494 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 61 participants.
The verdict
NCT04472494, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
Interventions
- OTHER Placebo
- BIOLOGICAL Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2021-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04472494
The ClinicalTrials.gov registry entry for NCT04472494 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04472494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04472494 about?
NCT04472494 is a clinical study titled "Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise". The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
What is the current status of trial NCT04472494?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2020-10-14. Estimated completion is 2021-09-13.
What interventions are being tested in trial NCT04472494?
The interventions under investigation include: Placebo (OTHER), Abatacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT04472494?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.